LIFESTYLE

TECHNOLOGY

LATEST NEWS

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in...

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for...

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger...

Jul. 1, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger...

STAY CONNECTED

218,514FansLike
66,788FollowersFollow
25,603SubscribersSubscribe

POPULAR ARTICLES

Neuroscience Professor Studies Environmental Influence in Huntington’s Disease

Growing up in Ghana, Visiting Assistant Professor of Neuroscience Gunnar Kwakye kept hearing stories about his great-grandfather. A man who worked on a farm...

Unraveling the mysteries of the mitochondria in Huntington’s disease – and getting fast, clear,...

In the collaborative quest for Huntington’s disease treatments, deepening affected families’ understanding of the key scientific challenges is vital. It can demystify the process...

uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual...

-- One-time Administration of AMT-130 Demonstrates for the First Time Efficacy in Large Animal Model -- Strong Dose-Dependent Reduction of Mutant Huntingtin Protein and Widespread...

LATEST REVIEWS

EuroBuzz News: Day 1

 Our first daily report from the European Huntington’s Disease Network Meeting in Stockholm. Follow us live for the second day on Twitter or Facebook...
0 Condivisioni